Adam Hill

Adam received his PhD from Imperial College, London after studying at the National Heart and Lung Institute with Prof Rebecca Sitsapesan and Prof Alan Williams. After an initial postdoctoral term at the Centre for Immunology, St. Vincent’s Hospital, he joined the Victor Chang Cardiac Research Institute in 2005 as part of the Mark Cowley Lidwill Research Program in Cardiac Electrophysiology. In 2011 he founded the Computational Cardiology Research Group of which he is now leader. He is also a conjoint Senior Lecturer at St. Vincent’s Clinical School, University of New South Wales.

Adam’s work has received competitive national grant funding from the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC) and the National Heart Foundation of Australian (NHFA) as well as international funding from the Safety Pharmacology Society and Health Research Council (NZ). He was awarded a NHFA postdoctoral fellowship in 2008 followed by both an ARC Future fellowship and NSW Cardiovascular Research Network Career Development Fellowship in 2011. He regularly reviews for international journals, national and international grant bodies and is a member of NHMRC grant review panels (GRP).

In the past few years Adam has been invited to deliver lectures at major international meetings including the CiPA workshop (Toronto, Canada, 2017), Biophysical Society (New Orleans, US, 2017), Safety Pharmacology Society (Vancouver, Canada, 2016), Cardiac Physiome (Auckland, NZ, 2016), International Society for Nephrology (Melbourne, 2016), Ion Channel Retreat (Vancouver, Canada, 2015) and the Asia-Pacific Heart Rhythm Society (Melbourne, 2015). Over the same period his work has bene published in top tier journals including Cell, Nature Communications, and Nature Structural and Molecular Biology. His work on drug binding to hERG K+ channels, the major cause of drug induced cardiac arrhythmias, resulted in his invitation to sit on the international committee advising the US FDA and Safety Pharmacology Society (SPS) on the development of a comprehensive in vitro proarrhythmia assay (CiPA initiative), the biggest change to preclinical drug screening regulation in generations. He has also filed four patents related to new computational techniques and algorithms for prediction of arrhythmia from patient ECGs.